ScholarIQanswers from OpenAlex & ORCID
Anne-Els van de Logt
ResearcherPublications, citations & collaboration network
Anne-Els van de Logt is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Anne-Els van de Logt have?
ScholarIQindexed works
Anne-Els van de Logt has 53 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Anne-Els van de Logt have?
ScholarIQcitation count
Anne-Els van de Logt has 1,298 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Anne-Els van de Logt?
ScholarIQh-index
Anne-Els van de Logt has an h-index of 16 in OpenAlex.
What is the i10-index of Anne-Els van de Logt?
ScholarIQi10-index
Anne-Els van de Logt has an i10-index of 17 in OpenAlex.
What is the OpenAlex record for Anne-Els van de Logt?
ScholarIQopenalex
The OpenAlex for Anne-Els van de Logt is on the source record.
What are the most-cited papers on Anne-Els van de Logt?
ScholarIQmost cited works
The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy
Gema Fernández‐Juárez, Jorge Rojas-Rivera, Anne-Els van de Logt, Joana Justino, Ángel Sevillano, Fernando Caravaca‐Fontán, Ana Ávila, Cristina Rabasco, Virginia Cabello, Alfonso Varela, Montserrat Díez, Guillermo Martín-Reyes, Marian Goicoechea Diezhandino, Luís F. Quintana, Irene Agraz, Juan Ramón Gomez-Martino, Mercedes Cao, Antolina Rodríguez-Moreno, Begoña Rivas, C. Galéano, J. Vilar Bonet, Ana Romera, Amir Shabaka, Emmanuelle Plaisier, Mario Espinosa, Jesús Egido, Alfonso Segarra, Gérard Lambeau, Pierre Ronco, Jack F.M. Wetzels, Manuel Praga, Manuel Praga, Ángel Sevillano, Fernando Caravaca‐Fontán, Hernando Trujillo, Eduardo Gutiérrez, Gema Fernández Juárez, Amir Shabaka, Jorge Rojas-Rivera, Jesús Egido, Alberto Ortíz, Marián Goicoechea, Úrsula Verdalles, Alfons Segarra, Irene Agraz, Guillermo Martín-Reyes, Lara Perea, Ildefonso Valera, Mónica Martín, Virginia Cabello, Miguel Ángel Pérez Valdivia, Luís F. Quintana, Miquel Blasco, Mercedes Cao, Andrés López Muñíz, Ana Ávila, T Małek, Mario Espinosa, Cristina Rabasco, Montserrat Díaz, Iara daSilva, Jordi Bonet, Maruja Navarro, Juan Ramón Gomez-Martino, Begoña Rivas, Antolina Rodríguez-Moreno, C. Galéano, Ana Romera, Ana Huerta, E. Rodriguez-Paternina, Ana Vigil, Roberto Alcázar, Vicente Paraíso, V. Barrio, Jack F.M. Wetzels, Anne-Els van de Logt, Julia M. Hofstra
The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery
Anne-Els van de Logt, Maryline Fresquet, Jack F.M. Wetzels, Paul Brenchley
Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy
Christelle Zaghrini, Barbara Seitz‐Polski, Joana Justino, Guillaume Dolla, Christine Payré, Noémie Jourde‐Chiche, Anne-Els van de Logt, Caroline Booth, Emma Rigby, Jennie Lönnbro-Widgren, Jenny Nyström, Christophe Mariat, Zhao Cui, Jack F.M. Wetzels, Gian Marco Ghiggeri, Laurence H. Beck, Pierre Ronco, Hanna Dêbiec, Gérard Lambeau
Immunological remission in PLA2R-antibody–associated membranous nephropathy: cyclophosphamide versus rituximab
Anne-Els van de Logt, Karine Dahan, Alexandra Rousseau, Renate G. van der Molen, Hanna Dêbiec, Pierre Ronco, Jack F.M. Wetzels
Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-up
Anne-Els van de Logt, Julia M. Hofstra, Jack F.M. Wetzels